Skip to main content
Premium Trial:

Request an Annual Quote

Celera and Seattle Genetics to Develop Antibody-Based Cancer Therapies

NEW YORK, July 21 (GenomeWeb News) - Celera Genomics and Seattle Genetics will collaborate to discover and develop targeted antibody-based therapies for cancer, the companies said today.


The companies will use Celera's proteomics platform to identify specific cell-surface proteins as antigen targets, and Seattle Genetics will screen against those targets to discover corresponding monoclonal antibodies, or antibodies linked to cell-killing compounds.


Celera and Seattle Genetics will co-fund preclinical and clinical drug development, and share any profits arising from commercialization, the companies said. In addition, either company may opt out of co-development for a particular product and receive royalties on net sales.


Celera will contribute cell-surface antigens identified in ongoing proteomics studies in the areas of pancreatic, lung, colon, and breast cancer.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.